Syntaxin raises $33M for biologics

11/1/2007 | Reuters

GlaxoSmithKline's venture-capital unit SR One co-led a new funding round that raised $33 million for Syntaxin Ltd. The firm is trying to develop experimental biologics for the treatment of pain and nervous, respiratory and metabolic disorders using a protein-based technology that controls the aberrant secretion of hormones linked to diseases.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR